EARNINGS

* Abbott Laboratories said second-quarter profit rose 6% to $685 million, or 44 cents a share, matching analyst forecasts, as sales grew 3% to $3.37 billion. Sales of Prevacid and some drugs used in anesthesia helped profit grow even as Abbott’s prostate drug, Hytrin, lost sales to generic competition in the U.S. Abbott is working to bring medical-test manufacturing in line with U.S. Food and Drug Administration regulations after it paid a record $100-million fine to the FDA for violations last year.